Sentences with phrase «cure for patients»
The phrase "a cure for patients" means a solution or treatment that helps to alleviate their symptoms, conditions or diseases. Full definition
We remain fully committed to developing a functional cure for all patients with insulin - requiring diabetes.
viacyte.com
The company's lead PEC - DirectTM product candidate is entering clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.
San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, announced today that the U.S. Food and Drug Administration (FDA) has allowed the company's Investigational New Drug Application (IND) for the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a potential cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
Led by Michael Fried, MD, web - based physician mentoring yields an impressive rate of cure for patients of the Rural Health Group.
When faced, for example, with the decision of whether or not to let a seriously ill or irreversible patient succumb voluntarily in terminal situations, we might avoid making the decision now, arguing for the possibility — maybe next week — that a new cure for the patient's condition will be discovered.
Hopefully, this new knowledge will help to find a future cure for patients who suffer such a devastating disease as LCA.»
Armed with knowledge of which mistakes in genes are driving which cancers, doctors and scientists will be able to maximise the chances of cure for each patient by picking the best treatments and by developing new and more targeted treatments for people with oesophageal and prostate cancers in the future.
In fact, City of Hope and the Translational Genomics Research Institute (TGen) recently joined forces to advance precision, or personalized, medicine and accelerate the speed with which scientists and medical staff convert research discoveries into cures for patients.
After implantation, the cells are expected to mature into the full complement of islet cells, including insulin - producing beta cells, offering a potential functional cure for patients with high - risk type 1 diabetes.
In addition, we believe that success with PEC - Direct is an important step on the path to a functional cure for all patients with type 1 diabetes, helping to fulfill our commitment of turning Type One into Type None.»
The funding will help support our current clinical trial evaluating the safety and efficacy of ViaCyte's PEC - Direct product candidate, which is in development as a potential cure for patients with high - risk type 1 diabetes.
Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.
From understanding the key biological functions to translating findings into treatments and cures for patients, the highly competitive awards and grants are crucial to the research across our schools of dentistry, medicine, nursing, pharmacy and the Graduate Division.
ViaCyte's product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.
To deliver a functional cure for all patients with type 1 diabetes and an important new therapy for patients with type 2 disease that require insulin to maintain control, ViaCyte is developing products with numerous advantages including a virtually unlimited supply of cells manufactured under quality - controlled conditions, and a potentially safer and more optimal route of administration.
«Of course, there are many years of additional studies that are required first, but this study provides hope for a cure for all patients with diabetes,» said John Buse, M.D., Ph.D., president of the American Diabetes Association and professor and chief of the endocrinology division in the UNC School of Medicine's department of medicine.
Susan L. Solomon is Founder and Chief Executive Officer of The New York Stem Cell Foundation Research Institute, the world's leading independent non-profit research institute dedicated to translating cutting - edge stem cell research into clinical breakthroughs and cures for patients.
Used with concomitant maintenance immune suppression therapy, the PEC - Direct product has the potential of delivering a sustained, functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
While PEC - Direct development could advance more rapidly and make a major impact for the subset of type 1 diabetes patients at highest risk, we view PEC - EnCap as holding the promise of a functional cure for all patients with type 1 diabetes as well as an important therapy for many patients with type 2 diabetes.»
«ViaCyte has a long history of firsts in the field of regenerative medicine and we believe working together with Gore to develop novel implantable cell therapy delivery device technologies will help us to achieve another important first, a functional cure for patients with type 1 diabetes.»
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
That's how my Ultimate Psoriasis Program treatment plan was born — out of my determination to find a cure for my patient's debilitating psoriasis symptoms, when their doctor told them that they would have to «live with it for the rest of their life» and stay with drugs and creams.
Arbutus Biopharma Corp. is a biopharmaceutical company, which focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus.
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
Alexandria, Virginia About Blog Kidney Cancer Research Alliance (KCCure) is a grassroots organization of patients, caregivers, doctors and medical researchers dedicated to eliminating suffering and death due to kidney cancer through increased funding to accelerate research that will lead to a cure for all patients and prevent future kidney cancer diagnoses.